In this episode, Joe interviews Nick Kadysh: Founder and CEO of PharmAla Biotech and member of the board of directors for The Canadian Psychedelic Businesses Association.

PharmAla Biotech is a Toronto-based Life Sciences company with two focuses: contracting with manufacturers to provide researchers with GMP MDMA (created under Good Manufacturing Practice regulations), and creating and researching novel analogs of MDMA. And just today, they announced that Health Canada has authorized them (and their distribution partner, Shaman Pharma) to supply their LaNeo™ MDMA for the treatment of a patient under Canada's Special Access Program – the first time this has happened in Canada.

He discusses the creation of PharmAla and why their model changed from primarily researching analogs to manufacturing; why they're operating out of Canada and using manufacturers instead of running the lab themselves; the excitement around Australia's recent about-face on MDMA and psilocybin-assisted therapy; the bureaucracy of U.S. drug policy and how much a broken supply chain affects the whole industry; bad IP and companies filing rapid fire patents; why creating new analogs of MDMA is so important; and why the psychedelic space needs to bring culture along with us.

He also talks about Spravato, cannabis and risks of cancer, THC nasal sprays, and research he's most excited about: that MDMA seems to alleviate dyskinesia caused from Parkinson's disease, and that MDMA could improve social anxiety in people with autism. He's aiming to run a clinical trial and believes they have developed a safe MDMA analog that the autistic community will respond to very well.

www.psychedelicstoday.com